TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03395080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg DKN-01
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg DKN-01
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg DKN-01
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg DKN-01
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600mg DKN-01
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600mg DKN-01
Description: Administered by IV infusion
Study: NCT02320773

Intervention type: DRUG
Intervention: Betmiga®
Description: Oral
Study: NCT03244631

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Plexus BLock
Description: Peripheral nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular injection
Description: Injection around the area undergoing surgery
Study: NCT03264924

Intervention type: BEHAVIORAL
Intervention: IPAIR
Description: Motivational interview training

Intervention type: BEHAVIORAL
Intervention: IPAIR
Description: Motivational interview training
Study: NCT01413750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT01074892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Provera (medroxyprogesterone)
Description: 10 mg per oral tablet. One tablet per day for 6 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirena (levonorgestrel)
Description: Inserted in the uterine cavity and kept in situ for 6 months
Study: NCT02531763

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social incentive intervention
Description: Participant sign a pre-commitment pledge to try to achieve their goal. They are entered into a game with their teammate in which they have the chance to earn points and advance through levels (bronze, silver, gold, platinum). At the end, those in gold or platinum will receive a coffee mug as a reward
Study: NCT02237235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMFS-202-302
Description: Active ingredient: L-Threonic acid Magnesium salt.~1 g (2 pills) by mouth once daily in the evening for 9 weeks~Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt~1 g (2 pills) by mouth once daily in the morning for 9 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.
Study: NCT01519388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing
Description: study of the swallowing of boluses of water and yogurt under spontaneous breathing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elysée 150®
Description: Study of the swallowing of boluses of water and yogurt while under mechanical ventilation
Study: NCT05566808

Intervention type: OTHER
Group type: OTHER
Intervention: Autologous Costal Cartilage Graft
Description: Subjects undergoing either reconstructive or cosmetic rhinoplasty will choose which graft will be used in their intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Costal Cartilage Allograft.
Description: Subjects undergoing either reconstructive or cosmetic rhinoplasty will choose which graft will be used in their intervention.
Study: NCT01003522

Intervention type: OTHER
Group type: OTHER
Intervention: Arterial puncture
Description: Patients will undergo arterial blood gas sampling from the radial artery. This will be done by experienced doctors who are highly skilled in this procedure.

Intervention type: OTHER
Group type: OTHER
Intervention: Arterial puncture
Description: Patients will undergo arterial blood gas sampling from the radial artery. This will be done by experienced doctors who are highly skilled in this procedure.

Intervention type: OTHER
Group type: OTHER
Intervention: Venepuncture
Description: Blood samples for baseline biochemistry, full blood count, and clotting screen will be taken. In patients additionally providing optional consent blood will be taken for laboratory based basic science research into lung cancer carcinogenesis and pharmacogenetics. Blood will be taken by qualified and experienced nurses, doctors and phlebotomists.

Intervention type: OTHER
Group type: OTHER
Intervention: Venepuncture
Description: Blood samples for baseline biochemistry, full blood count, and clotting screen will be taken. In patients additionally providing optional consent blood will be taken for laboratory based basic science research into lung cancer carcinogenesis and pharmacogenetics. Blood will be taken by qualified and experienced nurses, doctors and phlebotomists.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: General anaesthetic
Description: Patients randomised into the stenting arm will undergo rigid bronchoscopy under general anaesthetic.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inpatient stays
Description: Patients randomised into the stenting arm will be admitted overnight for the procedure

Intervention type: OTHER
Group type: OTHER
Intervention: Walking test
Description: All patients will be asked to complete a 6 minute walking test at baseline and on day 15. Patients randomised into the stent arm (Arm A) will complete a further 6 minute walking test at 24 hours post-stent

Intervention type: OTHER
Group type: OTHER
Intervention: Walking test
Description: All patients will be asked to complete a 6 minute walking test at baseline and on day 15. Patients randomised into the stent arm (Arm A) will complete a further 6 minute walking test at 24 hours post-stent

Intervention type: OTHER
Group type: OTHER
Intervention: Spirometry & flow volume loop assessment
Description: All patients will undergo spirometry and flow volume loop assessments at baseline and on day 15.

Intervention type: OTHER
Group type: OTHER
Intervention: Spirometry & flow volume loop assessment
Description: All patients will undergo spirometry and flow volume loop assessments at baseline and on day 15.

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy material
Description: For patients randomised to stenting and giving additional voluntary consent, 2 pairs of biopsies of tumour tissue, and 1 pair of biopsies of normal airways tissue will be taken for basic scientific research into lung cancer carcinogenesis, and pharmacogenetics.
Study: NCT04096014

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure Enlive
Description: The subjects in the intervention group will receive two Ensure Enlive supplements per day for 180 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Of Care
Description: The subjects in the Standard of care group will continue to receive the standard clinical therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Of Care
Description: The subjects in the Standard of care group will continue to receive the standard clinical therapy.
Study: NCT03346538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion high-dose MCI-186
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion low-dose MCI-186
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion placebo
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Approved dosing regimen MCI-186
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Approved dosing regimen placebo
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Approved dosing regimen placebo
Description: intravenous injection
Study: NCT04513522

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT02823821

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Default dialysate sodium concentration of 137mmol/l
Description: Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Default dialysate sodium concentration of 140mmol/l
Description: Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
Study: NCT04524078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive integrated intervention care program
Description: intensive integrated intervention care program \[ICP\] (lifestyle changes, patient education, adherence to practical guidelines) to transient ischemic attack or minor stroke patients would modify a variety of vascular risk factors and therefore should decrease the likelihood of recurrent stroke or vascular events
Study: NCT03188796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: oral/enteral loading dose of 37.5 ml MCT including 540,000 IU vitamin D3 followed by 10 drops daily (4000 IU) for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days
Study: NCT04070989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THA
Description: Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THA
Description: Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THA
Description: Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem
Study: NCT01927744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth daily continuously until the day before surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 150 mg by mouth daily continuously until the day before surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Phone call made to patient 1 time each year after the end of treatment visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Phone call made to patient 1 time each year after the end of treatment visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
Study: NCT04155333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that stimulates the brain through the application of a low-intensity electrical current, typically ranging from 1 to 2 milliamps (mA), via electrodes placed on an individual's scalp. During the active stimulation sessions, 2 mA of stimulation will be applied for 30 minutes. During the sham stimulation session, 2 mA of stimulation will be applied over the course of 90 sec, the electrodes will remain in place for the 30 minute duration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that stimulates the brain through the application of a low-intensity electrical current, typically ranging from 1 to 2 milliamps (mA), via electrodes placed on an individual's scalp. During the active stimulation sessions, 2 mA of stimulation will be applied for 30 minutes. During the sham stimulation session, 2 mA of stimulation will be applied over the course of 90 sec, the electrodes will remain in place for the 30 minute duration.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that stimulates the brain through the application of a low-intensity electrical current, typically ranging from 1 to 2 milliamps (mA), via electrodes placed on an individual's scalp. During the active stimulation sessions, 2 mA of stimulation will be applied for 30 minutes. During the sham stimulation session, 2 mA of stimulation will be applied over the course of 90 sec, the electrodes will remain in place for the 30 minute duration.
Study: NCT02942628

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vegetarian diet followed by meat diet or vice versa
Description: Half the patients will follow either a vegetarian diet for 6 weeks and the other half will adhere to or a meat-based diet for six weekd. This is followed by a 4 week period where patients eat their usual diet. Thereafter patients initially randomized to a vegetarian diet will follow a meat-based diet for six weeks while the patients initially randomized to meat will follow a vegetarian diet for six weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetarian diet followed by meat diet or vice versa
Description: Half the patients will follow either a vegetarian diet for 6 weeks and the other half will adhere to or a meat-based diet for six weekd. This is followed by a 4 week period where patients eat their usual diet. Thereafter patients initially randomized to a vegetarian diet will follow a meat-based diet for six weeks while the patients initially randomized to meat will follow a vegetarian diet for six weeks.
Study: NCT01954758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized Embryo Transfer (pET)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frozen Embryo Transfer (FET)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Embryo Transfer (ET)
Study: NCT00981578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2100
Description: Conformal Bone System
Study: NCT02966418

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mild Hypoxia Preconditioning
Description: Patients will be treated with mild hypoxia ( Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%)×7 days，twice a day in the morning and in the afternoon before surgery.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham preconditioning
Description: Patients will be treated with sham preconditioning (oxygen concentration: 21％) ×7 days，twice a day in the morning and in the afternoon before surgery.
Study: NCT01086878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cotrimoxazole
Description: Daily oral cotrimoxazole suspension from 1 to 6 months of age at the following weight-based doses:~* less than 5kg: 100mg sulfamethoxazole, 20mg trimethoprim~* greater than 5kg: 200mg sulfamethoxazole, 40mg trimethoprim
Study: NCT00424177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: experimental
Study: NCT02637557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI
Description: All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium sesquihydrate, rabeprazole or rabeprazole sodium) during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI
Description: All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium sesquihydrate, rabeprazole or rabeprazole sodium) during the study.
Study: NCT03537586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: After diagnostic catheterization, intravenous bivalirudin (Angiomax) will be administered as part of the research procedure, and a 6F-guiding catheter without side holes will be used to engage the ostium of the coronary artery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: An intravenous infusion of adenosine (140 μg/kg/min) will be administered via a large peripheral or central vein to induce steady-state maximal hyperemia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Heparin may be used as an alternative to bivalirudin at the discretion of the interventional cardiologist.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure-Temperature Sensor Guidewire
Description: Abbott's Pressure Wire X will be used to measure fractional flow reserve (FFR), cardiac magnetic resonance (CMR) and Index of Microcirculatory Resistance (IMR) in the Left Anterior Descending (LAD) Artery and major epicardial coronary vessels associated with myocardial ischemia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guiding Catheter
Description: Medtronic's 6F Launcher Guide Catheter will be used to engage the left main coronary artery.
Study: NCT04573543

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of the degree of fibrosis and steatosis
Description: The degree of steatosis will be estimated using the controlled attenuation parameter (CAP), a method for grading steatosis by measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of fibrosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of the degree of fibrosis and steatosis
Description: The degree of steatosis will be estimated using the controlled attenuation parameter (CAP), a method for grading steatosis by measuring the degree of ultrasound attenuation by hepatic fat using a process based on simultaneous transient elastography (TE) which measures the degree of fibrosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for the components of metabolic syndrome
Description: Anthropometric measures including body mass index (BMI), waist circumference (WC), waist hip ratio (WHR), and waist height ratio (WHtR) will be measured in all patients.~Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: bilirubin, AST, ALT, GGT, ALP, albumins, WBC, neutrophil-to-lymphocyte ratio, hemoglobin, platelet count, fasting glucose, triglycerides, cholesterol, HDL and LDL. Non-invasive scores of steatosis/fibrosis will be calculated (APRI, FIB4, NAFLD score). Patients will be screened for the components of metabolic syndrome.

Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for the components of metabolic syndrome
Description: Anthropometric measures including body mass index (BMI), waist circumference (WC), waist hip ratio (WHR), and waist height ratio (WHtR) will be measured in all patients.~Results of the routine laboratory tests as part of the standard diagnostic procedure will be collected: bilirubin, AST, ALT, GGT, ALP, albumins, WBC, neutrophil-to-lymphocyte ratio, hemoglobin, platelet count, fasting glucose, triglycerides, cholesterol, HDL and LDL. Non-invasive scores of steatosis/fibrosis will be calculated (APRI, FIB4, NAFLD score). Patients will be screened for the components of metabolic syndrome.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of serum semaphorin concentrations
Description: Semaphorin concentration will be measured in patient sera by ELISA.
Study: NCT02150109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subjects WITH/WITHOUT Diabetes Use Karajishi Contour BGMS
Description: Untrained subjects WITH and WITHOUT diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subjects WITH Diabetes Use Karajishi Contour BGMS
Description: Untrained subjects WITH diabetes use the Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
Study: NCT00768209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine and Topiramate
Description: Each subject will be dosed with a single oral dose of VI-0521 (PHEN/TPM 15/92 mg).
Study: NCT01626677

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CARTISTEM
Description: A single dose of 500㎕/㎠ of cartilage defect

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Active control
Study: NCT03291873

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRK
Description: PRK using Alcon-Wavelight Excimer Laser EX 500